Literature DB >> 1658308

Opioid receptor activity of GI 87084B, a novel ultra-short acting analgesic, in isolated tissues.

M K James1, P L Feldman, S V Schuster, J M Bilotta, M F Brackeen, H J Leighton.   

Abstract

GI 87084B (3-[4-methoxycarbonyl-4-[(1-oxopropyl) phenylamino]1-piperidine]propanoic acid, methyl ester, hydrochloride) was found to be a potent opioid agonist in the guinea pig ileum (EC50 = 2.4 +/- 0.6 nM), the rat vas deferens (EC50 = 387 +/- 44 nM) and the mouse vas deferens (EC50 = 39.5 +/- 7.4 nM). In the guinea pig ileum, GI 87084B, was roughly equivalent in potency to fentanyl (EC50 = 1.8 +/- 0.4 nM). GI 87084B was more potent in this tissue than alfentanil (EC50 = 20.1 +/- 1.2 nM) and less potent than sufentanil (EC50 = 0.3 +/- 0.09 nM). Schild analyses of antagonism of GI 87084B by naloxone yielded pKB values of 8.2 and slopes indistinguishable from unity in the guinea pig ileum and the mouse vas deferens. Insurmountable antagonism of GI 87084B by naloxone was observed in the rat vas deferens. However, an empirical measure of antagonist potency could be made: apparent pA2 = 8.1. The agonist dissociation constant (KA) for GI 87084B (220 +/- 90 nM) was determined by receptor alkylation with beta-chlornaltrexamine in the guinea pig ileum. Calculation of receptor occupancy suggested poor receptor-effector coupling and limited receptor reserve in the rat vas deferens, which could explain the insurmountable antagonism seen with higher concentrations of naloxone. These data suggest that GI 87084B acted through the mu class of opioid receptors to inhibit contraction induced by field stimulation in these tissues.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1658308

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  29 in total

Review 1.  Remifentanil: a review of its use during the induction and maintenance of general anaesthesia.

Authors:  Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Patient-controlled analgesia with remifentanil versus alternative parenteral methods for pain management in labour.

Authors:  Stephanie Weibel; Yvonne Jelting; Arash Afshari; Nathan Leon Pace; Leopold Hj Eberhart; Johanna Jokinen; Thorsten Artmann; Peter Kranke
Journal:  Cochrane Database Syst Rev       Date:  2017-04-13

Review 3.  Role of active metabolites in the use of opioids.

Authors:  Janet K Coller; Lona L Christrup; Andrew A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

Review 4.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

5.  Correction to: Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review.

Authors:  Victoria C Ziesenitz; Janelle D Vaughns; Gilbert Koch; Gerd Mikus; Johannes N van den Anker
Journal:  Clin Pharmacokinet       Date:  2018-03       Impact factor: 6.447

Review 6.  Opioid-induced cardioprotection.

Authors:  Katsuya Tanaka; Judy R Kersten; Matthias L Riess
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 7.  Remifentanil.

Authors:  S S Patel; C M Spencer
Journal:  Drugs       Date:  1996-09       Impact factor: 9.546

Review 8.  The clinical pharmacology of remifentanil: a brief review.

Authors:  Talmage D Egan
Journal:  J Anesth       Date:  1998-12       Impact factor: 2.078

Review 9.  [Remifentanil-based intraoperative anaesthesia and postoperative pain therapy. Is there an optimal treatment strategy?].

Authors:  C Zöllner; M Schäfer
Journal:  Anaesthesist       Date:  2007-10       Impact factor: 1.041

10.  Cardioprotective Effects of Remifentanil in a Sympathetic Hyperactivity Model in Rabbits.

Authors:  Selen Bayındır; Necati Gökmen; Serhat Erbayraktar; Semih Küçükgüçlü; Osman Yılmaz; Ömer Şahin; Elvan Öçmen; Hale Aksu Erdost; Emel Sağıroğlu
Journal:  Turk J Anaesthesiol Reanim       Date:  2015-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.